Overview

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Status:
Active, not recruiting
Trial end date:
2023-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to allow continued use of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals